1246765-28-5

Basic information

• Product Name: (3-Oxo-3,4-dihydro-2H-benzo[b]-[1,4]oxazin-6-yl)boronic acid
• Synonyms: (3-Oxo-3,4-dihydro-2H-benzo[b]-[1,4]oxazin-6-yl)boronic acid
• CAS NO: 1246765-28-5
• Molecular Formula: C8H8BNO4
• Molecular Weight: 192.96442
• Mol File: 1246765-28-5.mol

Chemical Properties

• Appearance: /
• Density: 1.46±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 8.06±0.20(Predicted)
• CAS DataBase Reference: (3-Oxo-3,4-dihydro-2H-benzo[b]-[1,4]oxazin-6-yl)boronic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (3-Oxo-3,4-dihydro-2H-benzo[b]-[1,4]oxazin-6-yl)boronic acid(1246765-28-5)
• EPA Substance Registry System: (3-Oxo-3,4-dihydro-2H-benzo[b]-[1,4]oxazin-6-yl)boronic acid(1246765-28-5)

Safety Data

• Hazardous Substances Data: 1246765-28-5(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(3-Oxo-3,4-dihydro-2H-benzo[b]-[1,4]oxazin-6-yl)boronic acid is used as a versatile building block in organic synthesis for the construction of various functional molecules. Its boronic acid group enables selective reactions with other molecules, facilitating the formation of carbon-carbon and carbon-heteroatom bonds.
Used in Pharmaceutical Development:
In the pharmaceutical industry, (3-Oxo-3,4-dihydro-2H-benzo[b]-[1,4]oxazin-6-yl)boronic acid is used as a key intermediate in the synthesis of bioactive compounds. Its reactivity and structural features make it suitable for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Applications:
(3-Oxo-3,4-dihydro-2H-benzo[b]-[1,4]oxazin-6-yl)boronic acid is employed in the agrochemical industry as a precursor for the synthesis of novel agrochemicals. Its unique properties allow for the creation of compounds with improved biological activity and selectivity, contributing to the development of more effective and environmentally friendly pesticides and herbicides.
Used in Materials Science:
In materials science, (3-Oxo-3,4-dihydro-2H-benzo[b]-[1,4]oxazin-6-yl)boronic acid is utilized as a component in the design and synthesis of advanced materials. Its reactivity and structural features can be exploited to create materials with specific properties, such as improved mechanical strength, thermal stability, or electrical conductivity, for various applications in industries like electronics, aerospace, and automotive.

Upstream product

• 943994-02-3 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-benzo[b][1,4]oxazin-3(4H)-one 
• 24036-52-0 6-bromo-3,4-dihydro-2H-1,4-benzoxazin-3-one 
• 13675-18-8 tetrahydroxydiboron 

Relevant articles and documents

Pd- And Ni-Based Systems for the Catalytic Borylation of Aryl (Pseudo)halides with B2(OH)4

Despite recent advancements in metal-catalyzed borylations of aryl (pseudo)halides, there is a continuing need to develop robust methods to access both early-stage and late-stage organoboron intermediates amendable for further functionalization. In particular, the development of general catalytic systems that operate under mild reaction conditions across a broad range of electrophilic partners remains elusive. Herein, we report the development and application of three catalytic systems (two Pd-based and one Ni-based) for the direct borylation of aryl (pseudo)halides using tetrahydroxydiboron (B2(OH)4). For the Pd-based catalyst systems, we have identified general reaction conditions that allow for the sequestration of halide ions through simple precipitation that results in catalyst loadings as low as 0.01 mol % (100 ppm) and reaction temperatures as low as room temperature. We also describe a complementary Ni-based catalyst system that employs simple unligated Ni(II) salts as an inexpensive alternative to the Pd-based systems for the borylation of aryl (pseudo)halides. Extrapolation of all three systems to a one-pot tandem borylation/Suzuki-Miyaura cross-coupling is also demonstrated on advanced intermediates and drug substances.

4, 5-DIHYDRO-LH-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES

Mineralocorticoid receptor antagonists (MRa), pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetic nephropathy and hypertension in mammals, including humans.